Prognostic role of CRP‐independent inflammatory patterns in patients undergoing primary percutaneous interventions

Despite the key pathophysiological role of inflammation in the development of coronary artery disease (CAD), the evaluation of inflammatory status has not been clearly established in patients presenting with acute coronary syndrome (ACS). The aim of this study is to evaluate the prevalence of CRP‐independent inflammatory patterns in patients referred for primary percutaneous coronary intervention (pPCI) and to determine their one‐year relationship with adverse clinical outcomes.

[1]  Theresa M. Beckie,et al.  2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2021, Journal of the American College of Cardiology.

[2]  F. Yıldız,et al.  Systemic Immune-inflammation Index (SII) Predicts Pathological Complete Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. , 2021, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP.

[3]  E. Kızıltunç,et al.  Relationship Between Systemic Immune-Inflammation Index (SII) and the Severity of Stable Coronary Artery Disease , 2021, Angiology.

[4]  V. Regitz-Zagrosek,et al.  Colchicine in Patients with Chronic Coronary Disease. , 2021, The New England journal of medicine.

[5]  A. Kurtul,et al.  Systemic immune-inflammation index predicts no-reflow phenomenon after primary percutaneous coronary intervention , 2021, Acta cardiologica.

[6]  D. Maucort-Boulch,et al.  Colchicine for Left Ventricular Infarct Size Reduction in Acute Myocardial Infarction: A Phase II, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Protocol – The COVERT-MI Study , 2021, Cardiology.

[7]  Qian Yan,et al.  Systemic immune-inflammation index (SII): A More Promising Inflammation-Based Prognostic Marker for Patients with synchronic colorectal peritoneal carcinomatosis , 2020, Journal of Cancer.

[8]  Yenn-Jiang Lin,et al.  Systemic immune‐inflammation index (SII) predicted clinical outcome in patients with coronary artery disease , 2020, European journal of clinical investigation.

[9]  Binita Shah,et al.  Effects of Acute Colchicine Administration Prior to Percutaneous Coronary Intervention , 2020, Circulation. Cardiovascular interventions.

[10]  H. Nie,et al.  Atheroprotective effects of methotrexate via the inhibition of YAP/TAZ under disturbed flow , 2019, Journal of Translational Medicine.

[11]  G. Hindricks,et al.  2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. , 2019, Atherosclerosis.

[12]  Qingshan Wang,et al.  The prognostic value of systemic immune-inflammation index (SII) in patients after radical operation for carcinoma of stomach in gastric cancer. , 2019, Journal of gastrointestinal oncology.

[13]  P. Libby,et al.  Low‐Dose Methotrexate for the Prevention of Atherosclerotic Events , 2019, The New England journal of medicine.

[14]  Samin K. Sharma,et al.  Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions , 2018, European heart journal.

[15]  K. Rayner,et al.  Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions. , 2018, Atherosclerosis.

[16]  Volkmar Falk,et al.  2018 ESC/EACTS Guidelines on myocardial revascularization. , 2018, European heart journal.

[17]  C. Carru,et al.  Blood cell count indexes as predictors of outcomes in advanced non-small-cell lung cancer patients treated with Nivolumab , 2018, Cancer Immunology and Immunotherapy.

[18]  Marco Valgimigli,et al.  2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). , 2018, European heart journal.

[19]  P. Libby,et al.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.

[20]  B. Li,et al.  Inflammation: A Novel Therapeutic Target/Direction in Atherosclerosis , 2017, Current pharmaceutical design.

[21]  Hong-zhao Li,et al.  Prognostic value of a systemic inflammatory response index in metastatic renal cell carcinoma and construction of a predictive model , 2016, Oncotarget.

[22]  Paul M Ridker,et al.  Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin. , 2016, European heart journal.

[23]  J. Neoptolemos,et al.  Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. , 2009, American journal of surgery.

[24]  Yao Sun.  Myocardial repair/remodelling following infarction: roles of local factors. , 2008, Cardiovascular research.

[25]  G. Parodi,et al.  Prevalence, predictors, time course, and long-term clinical implications of left ventricular functional recovery after mechanical reperfusion for acute myocardial infarction. , 2007, The American journal of cardiology.

[26]  R. Schnabel,et al.  Inflammation, atherosclerotic burden and cardiovascular prognosis. , 2007, Atherosclerosis.

[27]  M. ChB.,et al.  Neutrophil‐lymphocyte ratio as a prognostic factor in colorectal cancer , 2005, Journal of surgical oncology.

[28]  L. Lind.  Circulating markers of inflammation and atherosclerosis. , 2003, Atherosclerosis.

[29]  Peter Libby,et al.  Current Concepts of the Pathogenesis of the Acute Coronary Syndromes , 2001, Circulation.

[30]  R. Poston,et al.  Immunity and inflammation in the pathogenesis of atherosclerosis. A review. , 1974, Atherosclerosis.

[31]  M. London.  ACC / AHA / SCAI Guideline for Coronary Artery Revascularization : Executive Summary : A Report of the American College of Cardiology / American Heart Association Joint Committee on Clinical Practice Guidelines , 2022 .

[32]  Helmut Baumgartner,et al.  ESC / EACTS Guidelines on myocardial revascularization , 2014 .

[33]  M. Taskinen,et al.  [ESC/EAS Guidelines for the management of dyslipidaemias]. , 2011, Revista espanola de cardiologia.

[34]  M. Febbraio,et al.  Role of inflammation in the pathogenesis of insulin resistance , 2008 .

[35]  Peter Libby,et al.  Innate and Adaptive Immunity in the Pathogenesis of Atherosclerosis , 2002, Circulation research.